Prevymis Pellet
Product Images NDC 0006-5086

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Prevymis (NDC 0006-5086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Prevymis 01

Chemical structure diagram of LETERMOVIR, the active ingredient in PREVYMIS tablets. The diagram depicts the molecular arrangement and bonds of the compound.*

FDA Label Image

Prevymis 02

A cumulative incidence curve comparing Letermovir and Placebo for clinically significant CMV infection over 24 weeks post-transplant. The y-axis shows cumulative rate in percentage, and the x-axis shows weeks post-transplant from 0 to 24. Letermovir shows lower infection rates (6.8% at week 14, 18.9% at week 24) compared to Placebo (41.3% at week 14, 44.3% at week 24). Number of subjects at risk decreases over time for both groups.*

FDA Label Image

Prevymis 03

PREVYMIS (letermovir) tablets 240 mg film-coated oral tablets packaging label from Merck Sharp & Dohme LLC. The label shows a 28-tablet carton with a 28-day supply, indicating 1 tablet per day. The packaging is primarily green and white with blue and green accents, featuring the proprietary name PREVYMIS prominently, along with the strength 240 mg per tablet and the generic name letermovir.*

FDA Label Image

Prevymis 04

Packaging label for PREVYMIS (letermovir) tablets, 480 mg per tablet. The label indicates a 28-day supply with 28 tablets. It is a prescription oral film-coated tablet manufactured by Merck Sharp & Dohme LLC. The label includes dosage and storage instructions, the NDC code 0006-3076-02, and a small image of the pink tablet.*

FDA Label Image

Prevymis 05

Packaging label for Prevymis (letermovir) Injection 240 mg/12 mL (20 mg/mL) by Merck Sharp & Dohme LLC. The label indicates the product is for intravenous infusion only, with storage instructions and dosage information. It shows that each vial contains 240 mg of letermovir in 12 mL solution, includes ingredients, and has an Rx only designation with a single-dose vial note.*

FDA Label Image

Prevymis 06

Carton packaging label for Prevymis (letermovir) Injection 480 mg/24 mL (20 mg/mL) by Merck Sharp & Dohme LLC. The label indicates it is for intravenous infusion only and includes storage instructions, dosage form, dilution requirements, and ingredient details. The product is a single-dose vial injection with no preservative.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.